Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study

Mandana Nikpour1,2, Murray B Urowitz1*, Dominique Ibanez1, Paula J Harvey3 and Dafna D Gladman1

Abstract

Introduction: Previous studies have shown that traditional risk factors such as hypercholesterolemia and hypertension account for only a small proportion of the dramatically increased risk of atherosclerotic coronary artery disease (CAD) in systemic lupus erythematosus (SLE). However, in these studies, exposure to risk factors was measured only at baseline. In this study, our objective was to compare measures of cumulative exposure with remote and recent values for each of total cholesterol (TC), systolic (SBP), and diastolic (DBP) blood pressure in terms of ability to quantify risk of atherosclerotic CAD in patients with SLE.

Methods: Patients in the Toronto lupus cohort had TC and BP measured at each clinic visit and were followed up prospectively for the occurrence of CAD. For each patient, arithmetic mean, time-adjusted mean (AM) and area-under-the-curve (AUC) were calculated for serial TC, SBP, and DBP measurements. Proportional hazards regression models were used to compare these summary measures with recent and first-available ("remote") measurements in terms of ability to quantify risk of CAD events, defined as myocardial infarction, angina, or sudden cardiac death.

Results: The 991 patients had a mean ± SD of 19 ± 19 TC measurements per patient. Over a follow-up of 6.7 ± 6.4 years, 86 CAD events occurred; although remote TC was not significantly predictive of CAD, mean and AM TC were more strongly predictive (hazard ratio (HR) 2.07; P = 0.003) than recent TC (HR 1.86, P = 0.001). AUC TC was not predictive of CAD. A similar pattern was seen for DBP and SBP. Older age, male sex, higher baseline and recent disease activity score, and corticosteroid use also increased CAD risk, whereas antimalarials were protective.

Conclusions: In contrast to the population-based Framingham model, first-available TC and BP are not predictive of CAD among patients with SLE, in whom measures reflecting cumulative exposure over time are better able to quantify CAD risk. This is an important consideration in future studies of dynamic risk factors for CAD in a chronic relapsing-remitting disease such as SLE. Our findings also underpin the importance of adequate control of SLE disease activity while minimizing corticosteroid use, and highlight the cardioprotective effect of antimalarials.

* Correspondence: m.urowitz@utoronto.ca
1 University of Toronto Lupus Clinic and the Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada
Full list of author information is available at the end of the article

© 2011 Urowitz et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction
Systemic lupus erythematosus (SLE) is associated with a dramatically increased risk of atherosclerotic coronary artery disease (CAD), such that women with SLE aged 34 to 44 years are more than 50 times more likely to develop myocardial infarction (MI) than are age-matched peers [1]. Traditional risk factors measured at baseline, as defined in the Framingham model, do not fully account for this increased risk [2].

In the general population, it has been shown that recent and remote blood pressure (BP) predict cardiovascular risk incrementally over current BP [3]. In an inception cohort of patients with SLE, those with sustained hypercholesterolemia in the first 3 years of their disease were shown to be at greatest risk of cardiovascular events over 12 to 14 years of follow-up, compared with those who had persistently normal cholesterol or “variable” hypercholesterolemia in the first 3 years of disease [4]. We previously showed that both TC and BP take a variable course in patients with SLE and that almost half of the total variance over time in both TC and BP is seen within rather than between patients [5]. These findings suggest that the risk of future coronary events might be best quantified by using strategies that take into account multiple measurements of risk factors over time.

In this prospective proof-of-concept cohort study, we sought to compare “summary measures” of cumulative exposure to TC, SBP, and DBP, with single-point-in-time measurements of these risk factors (both recent and remote), in terms of ability to quantify CAD risk.

Materials and methods
Patients
Patients attending the University of Toronto lupus clinic are routinely seen at 2- to 6-monthly intervals wherein clinical and laboratory data, including TC, systolic blood pressure (SBP), and diastolic blood pressure (DBP) levels are obtained and recorded according to a set protocol. Patients are followed up prospectively for the occurrence of CAD events. In this study, we included patients who had two or more measurements of TC, SBP, and DBP taken before a CAD event (or last visit), in whom the gap between measurements did not exceed 18 months. Patients with a history of CAD before the start of the study were excluded. All patients fulfilled four or more of the American College of Rheumatology classification criteria for SLE, or had three criteria and a typical lesion of SLE on skin or renal biopsy [6,7]. Informed consent was obtained from all participants, and the study was approved by the research ethics board of the University Health Network.

Methods
Measurement of TC, SBP, and DBP
Each measurement of TC, SBP, and DBP was tied to a clinic visit. TC was measured in plasma by using a commercial assay (Boehringer Mannheim kit 236691, Indianapolis, IN, USA) and recorded in millimoles per liter. As only small, clinically insignificant differences in TC are found when measured in the fasting or nonfasting state, nonfasting samples were used [8]. SBPs and DBPs were measured in millimeters of mercury (mm Hg) at every visit by using a manual sphygmomanometer. The patient was allowed to rest for 5 minutes in the sitting position. The reading was taken on the right arm, supported at the level of the heart. Korotkoff phase V (disappearance) was recorded as DBP.

Calculation of “summary measures” of TC, SBP, and DBP
For each of TC, SBP, and DBP, an arithmetic mean of all available measurements in each patient was calculated as the sum of all individual measurements divided by the total number of measurements. In each patient, for each of TC, SBP, and DBP, a time-adjusted mean (AM) was also calculated by using the formula:

$$\text{AM} = \frac{\sum_{i=2}^{n} \left( \frac{x_i + x_{i-1}}{2} \right) t_i}{\sum_{i=2}^{n} t_i}$$

where $x_i$ is the level of the variable at visit $i$, and $t_i$ is the time interval between visit $i$ and $i-1$. By incorporating the time interval between measurements in its calculation, the AM takes into account the length of time that TC, SBP, and DBP are presumed to have remained at a particular level. The arithmetic mean and AM were reported in millimoles per liter for TC and millimeters of mercury for BP. In each patient, for each of TC, SBP, and DBP, the area-under-the-curve (AUC) was calculated by using integral calculus. AUC is reported in millimoles per liter multiplied by $t$ and millimeters mercury multiplied by $t$ for each of TC and BP, respectively, where $t$ is the unit of time, in this case, months. For any given visit ($V_i$), the summary measure for each of TC, SBP, and DBP was calculated from the first study visit ($V_1$) up to and including the visit before ($V_{i-1}$), thus ensuring that for all time intervals, exposure preceded outcome. The last visit ($V_L$) was either a visit at which a CAD event was recorded or the last clinic visit as of August 2008 in those who remained CAD free.

Covariates
Covariates included in the proportional hazards models were sex, age, disease duration, disease-activity score (Systemic Lupus Erythematosus Disease Activity Index 2000; SLEDAI-2K), anti-phospholipid antibodies, “other”
classic cardiovascular risk factors (diabetes and smoking), medications including corticosteroids, antimalarials, immunosuppressives, antihypertensives, and lipid-lowering therapy (statins), all recorded at baseline, and at each and every visit. Age and disease duration (from diagnosis to V_1) were reported in years. SLEDAI-2K is an organ-weighted index of disease activity, scored from 0 to 105, with higher scores indicating more-active disease [9]. Antimalarials included chloroquine and hydroxychloroquine. Immunosuppressives included methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, and cyclophosphamide. Antihypertensives included diuretics, β-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin type II receptor blockers. The cumulative corticosteroid dose over the period of follow-up from study entry (V_1) to the last visit (V_L) was calculated and reported in grams. Use of all other medications was reported categorically at each visit, irrespective of dose. Diabetes was defined as fasting plasma glucose > 7.0 mmol/L or diabetes therapy ever. Current smoking was defined as smoking an average of one or more cigarette/s per day in the past month.

Outcome variables

CAD events were angina pectoris, myocardial infarction (MI), and sudden cardiac death. MI was defined as one of definite electrocardiographic (ECG) abnormalities, or typical symptoms with probable ECG abnormalities and abnormal enzymes (≥2 times upper limit of normal), or typical symptoms and abnormal enzymes. Angina pectoris was defined as severe pain or discomfort over the upper or lower sternum or anterior left chest and left arm, of short duration, relieved by rest or vasodilators in the absence of active SLE, or in the presence of atherosclerotic vascular disease elsewhere (for example, atherosclerotic peripheral vascular or cerebrovascular disease). The diagnosis of angina and MI required confirmation by a cardiologist. Sudden cardiac death was defined as death with undetermined cause but presumed cardiac.

A CAD event that occurred between V_i and V_{i+1} was recorded at V_{i+1}. For patients who had more than one CAD event, only the first was used in analysis. Some patients may have had both angina and MI recorded for the first time at a particular visit; this was treated as only one event rather than two.

Univariate comparisons

For each of the TC and BP models, univariate comparisons of demographic, disease- and treatment-related variables and traditional cardiac risk factors in patients who had CAD events and those that remained CAD free were performed by using t tests for continuous variables and χ² tests for categoric variables. In case of non-normally distributed data, Mann-Whitney U tests were used for continuous variables. Two-sided P values (P) ≤ 0.05 were considered to be significant.

Time-constant regression models

For each of TC, SBP, and DBP, two time-constant proportional hazards models were run. Variables in the first model included first available (baseline) measurement of TC (or SBP, DBP), along with sex, age, SLEDAI-2K score at study entry (V_1 or “baseline”), and anti-phospholipid antibodies, diabetes, smoking, corticosteroid, antimalarial, immunosuppressive, antihypertensive, and lipid-lowering medication use “ever” from V_1 to V_{L-1}.

The second model included the average (arithmetic mean) of the first two available measurements of TC (or SBP or DBP) and all covariates included in the first Cox model.

Time-dependent regression models

For each of TC, SBP, and DBP, we also ran four time-dependent proportional hazards regression models. In the first model, recent measurements of TC (or SBP or DBP) were used in a dynamic manner, varying from visit to visit. In the remaining three models, summary measures (mean, AM, AUC) were used in a time-dependent manner (that is, updated from visit to visit). Covariates in these models included sex, age, SLEDAI-2K score, anti-phospholipid antibodies, diabetes, smoking, corticosteroid, antimalarial, immunosuppressive, antihypertensive and lipid-lowering medication use, also treated in a time-dependent fashion (that is, updated from visit to visit). For each of TC, SBP, and DBP at each visit, single point, mean, and AM measurements were strongly correlated. Therefore, each summary measure was analyzed in a separate model.

Both time-constant and time-dependent models are reported as hazard ratios (HRs) with accompanying 95% confidence interval (95% CI) and P value, for each of the predictor variables and covariates. All statistical analyses were performed by using the SAS software version 9.1 (SAS Institute, Inc., Cary, NC, U.S.A.).

Results

Characteristics of the patients in this study are presented in Table 1. Overall, the BP dataset contained 991 patients, whereas the TC dataset comprised 956 patients. In each dataset, patients were mostly female (88%) and mostly Caucasian (70%). A total of 94 coronary events occurred (75 angina, 25 MI, and two sudden cardiac deaths; eight had both angina and MI) in the BP dataset, whereas the TC dataset contained 86 coronary events (71 angina, 20 MI, and two sudden cardiac deaths; seven had both angina and MI). The mean ± SD age and disease duration at entry into the study were very similar for both datasets (37.1 ± 14.0 and 6.1 ± 7.9 years, respectively, for the BP dataset). Likewise, mean ± SD SLEDAI-2K score and Systemic Lupus
Table 1 Patient characteristics

|                              | BP Dataset |                   | TC Dataset |                   |
|------------------------------|------------|-------------------|------------|-------------------|
|                              | n (%) or mean ± SD | n (%) or mean ± SD |           |                   |
| Number of patients           | 991        | 956               |            |                   |
| Female                        | 879 (88.7%) | 849 (88.8%)       |            |                   |
| Race                          |            |                   |            |                   |
| Caucasian                     | 70%        | 70%               |            |                   |
| Black                         | 11%        | 11%               |            |                   |
| Asian                         | 11%        | 11%               |            |                   |
| Other                         | 8%         | 8%                |            |                   |
| CAD events                    |            |                   |            |                   |
| MI                            | 25         | 20                |            |                   |
| Angina                        | 75         | 71                |            |                   |
| Sudden cardiac death          | 2          | 2                 |            |                   |
| Total                         | 94         | 86                |            |                   |
| Age\(^a\)                     |            |                   |            |                   |
| At diagnosis                  | 310 ± 13.8 | 309 ± 13.8        |            |                   |
| At study entry                | 37.1 ± 14.0| 37.5 ± 14.1       |            |                   |
| Disease duration\(^a\)        |            |                   |            |                   |
| At first clinic visit         | 4.0 ± 5.8  | 4.0 ± 5.9         |            |                   |
| At study entry                | 6.1 ± 7.9  | 6.6 ± 8.1         |            |                   |
| SLEDAI-2K\(^b\)              |            |                   |            |                   |
| At first clinic visit         | 9.7 ± 7.7  | 9.6 ± 7.7         |            |                   |
| At study entry                | 9.2 ± 7.5  | 8.3 ± 7.2         |            |                   |
| SLICC/ACR-DI\(^c\)            |            |                   |            |                   |
| At first clinic visit         | 0.3 ± 0.7  | 0.3 ± 0.7         |            |                   |
| At study entry                | 0.5 ± 1.2  | 0.6 ± 1.2         |            |                   |
| Steroids at study entry       | 623 (63%)  | 625 (65.6%)       |            |                   |
| Antimalarials at study entry\(^d\) | 380 (38.5%) | 385 (40.4%)       |            |                   |
| Immunosuppressives\(^e\)     |            |                   |            |                   |
| At study entry                | 235 (23.8%)| 233 (24.5%)       |            |                   |
| Hypertension at study entry\(^f\) | 221 (22.3%) | 212 (22.6%)       |            |                   |
| Hypercholesterolemia at study entry\(^g\) | 344 (41.8%) | 408 (42.7%)       |            |                   |
| Diabetes at study entry\(^h\) | 28 (2.9%)  | 31 (3.3%)         |            |                   |
| Smoker at study entry\(^i\)  | 190 (19.5%)| 183 (19.5%)       |            |                   |
| Antihypertensive use at study entry\(^j\) | 174/691 (25.2%) | 174/699 (24.9%) |            |                   |
| Lipid-lowering meds at study entry\(^k\) | 23/440 (5.2%) | 22/440 (5.0%)     |            |                   |

BP, blood pressure (mm Hg); CAD, coronary artery disease; MI, myocardial infarction; SD, standard deviation; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; SLICC/ACR-DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; TC, total plasma cholesterol (mmol/L). \(^a\)Years. \(^b\)Scores range from 0 to 105, with higher scores indicating more-active disease. \(^c\)Scores range from 0 to 46, with higher scores indicating greater disease-related damage. \(^d\)Antimalarials include chloroquine and hydroxychloroquine. \(^e\)Immunosuppressives include methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, and cyclophosphamide. \(^f\)Diastolic BP ≥90 or systolic BP ≥140 mm Hg or treatment with antihypertensive medication. \(^g\)Hypercholesterolemia was defined as cholesterol > 5.2 mmol/L or lipid-lowering therapy. \(^h\)Diabetes was defined as fasting plasma glucose > 7.0 mmol/L or diabetes therapy. \(^i\)Current smoking is defined as smoking an average of one or more cigarettes per day over the past month. \(^j\)All classes of antihypertensives including diuretics, β-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin type II receptor blockers. \(^k\)HMG Co-A reductase inhibitors (statins).

Summary measures for BP
The calculation of summary measures was based on 19, 579 individual measurements of SBP and DBP, with a mean ± SD of 20 ± 20 (median, 13) serial measurements per patient. The mean ± SD (median) time interval between measurements was 4.2 ± 2.3 (3.4) months. The mean ± SD (median) time from study start to the visit before a CAD event (or last clinic visit) was 6.5 ± 6.7 (4.2) years. The mean ± SD (median) length of follow-up from study start to CAD event (or last clinic visit) was 7.0 ± 6.7 (4.6) years. Among all patients, the mean SBP at the start of study was 123.9 ± 19.4 mm Hg, whereas the mean DBP at the start of study was 77.6 ± 12.3 mm Hg.

Summary measures for TC
The calculation of summary measures was based on 17, 936 individual measurements of TC, with a mean ± SD of 19 ± 19 (median, 12) serial measurements per patient. The mean ± SD (median) time interval between TC measurements was 4.3 ± 2.3 (3.6) months. The mean ± SD (median) time from study start to the visit before a CAD event (or last clinic visit) was 6.3 ± 6.4 (4.2) years. The mean ± SD (median) length of follow-up from study start to CAD event (or last clinic visit) was 6.7 ± 6.4 (4.6) years. Among all patients, the mean TC level at the start of study was 5.3 ± 1.6 mmol/L.

Univariate comparisons
Univariate comparisons of patients with and without a CAD event for each of the BP and TC models are presented in Table 2. In the BP models, patients who experienced CAD events were more likely to be Caucasian (87.2% versus 68.6%; \(P = 0.004\)), older (46.0 ± 13.2 versus 36.6 ± 13.9 years; \(P = 0.0001\)), menopausal (44.4% versus 23.7%; \(P = 0.0001\)), hypertensive (31.0% versus 14.4%; \(P < 0.0001\)), and taking corticosteroids...
Table 2 Univariate comparison of patients with and without CAD used in TC and BP models

|                                | BP models       | TC models       |
|--------------------------------|-----------------|-----------------|
|                                | CAD (n = 94)    | No CAD (n = 897)|   | CAD (n = 86)    | No CAD (n = 870) |
|                                | n(%) or mean ±  | P               |   | n(%) or mean ±  | P               |
|                                | SD              |                 |   | SD              |                 |
| Female                         | 72 (83.7%)      | 777 (93.9%)     | 0.12 | 78 (83.0%)      | 801 (89.3%)     | 0.07 |
| Menopausea at study start      | 32 (44.4%)      | 184 (23.7%)     | 0.0001 | 33 (42.3%)      | 189 (23.6%)     | 0.0003 |
| Race                           |                 |                 |   |                 |                 |
| Caucasian                      | 75 (87.2%)      | 574 (68.6%)     | 0.004 | 81 (86.2%)      | 593 (68.7%)     | 0.005 |
| Black                          | 3 (3.5%)        | 96 (11.5%)      | 4 (4.3%) | 97 (11.2%)      |                 | |
| Asian                          | 4 (4.7%)        | 94 (11.2%)      | 4 (4.3%) | 97 (11.2%)      |                 | |
| Other                          | 4 (4.7%)        | 73 (8.7%)       | 5 (5.3%) | 76 (8.8%)       |                 | |
| Disease durationb              |                 |                 |   |                 |                 |
|                                |                 |                 |   |                 |                 |
|                                | 4.08 ± 5.71     | 4.01 ± 5.87     | 0.92 | 4.24 ± 5.72     | 3.94 ± 5.80     | 0.63 |
|                                | 6.99 ± 7.84     | 6.54 ± 8.17     | 0.62 | 5.95 ± 7.23     | 6.13 ± 8.00     | 0.83 |
| SLEDAI-2Kc                     |                 |                 |   |                 |                 |
|                                |                 |                 |   |                 |                 |
|                                | 12.34 ± 8.67    | 9.49 ± 7.63     | 0.001 | 12.16 ± 8.63    | 9.60 ± 7.65     | 0.002 |
|                                | 9.59 ± 7.99     | 8.28 ± 7.26     | 0.11 | 11.36 ± 8.86    | 9.02 ± 7.50     | 0.02 |
| Disease manifestationsd ever from diagnosis to first visit | | |   | | |
| Musculoskeletal                | 42 (44.7%)      | 365 (40.7%)     | 0.45 | 44 (51.2%)      | 363 (41.7%)     | 0.09 |
| Cutaneous                      | 69 (73.4%)      | 504 (56.2%)     | 0.001 | 65 (75.6%)      | 507 (58.3%)     | 0.002 |
| Renal                          | 46 (48.9%)      | 364 (40.6%)     | 0.12 | 47 (54.7%)      | 370 (42.5%)     | 0.03 |
| Nervous system                 | 32 (34.0%)      | 180 (20.1%)     | 0.002 | 32 (37.2%)      | 189 (21.7%)     | 0.001 |
| Hematologic                    | 13 (13.8%)      | 110 (12.3%)     | 0.66 | 14 (16.3%)      | 117 (13.5%)     | 0.47 |
| Vasculitis                     | 19 (20.2%)      | 126 (14.1%)     | 0.11 | 19 (22.1%)      | 133 (15.3%)     | 0.10 |
| Immunologic                    | 58 (61.7%)      | 640 (71.4%)     | 0.05 | 62 (72.1%)      | 637 (73.2%)     | 0.82 |
| Serosal                        | 13 (13.8%)      | 77 (8.6%)       | 0.09 | 11 (12.8%)      | 74 (8.5%)       | 0.18 |
| Fever                          | 16 (17.0%)      | 141 (15.7%)     | 0.74 | 18 (20.9%)      | 138 (15.9%)     | 0.23 |
| Disease manifestationsd ever during follow-up | | |   | | |
| Musculoskeletal                | 70 (74.5%)      | 508 (56.6%)     | 0.0008 | 67 (77.9%)      | 476 (54.7%)     | < 0.0001 |
| Cutaneous                      | 82 (87.2%)      | 643 (71.7%)     | 0.001 | 73 (84.9%)      | 615 (70.7%)     | 0.005 |
| Renal                          | 72 (76.6%)      | 581 (64.8%)     | 0.02 | 62 (72.1%)      | 547 (62.9%)     | 0.09 |
| Nervous system                 | 58 (61.7%)      | 304 (33.9%)     | < 0.0001 | 53 (61.6%)      | 284 (32.6%)     | < 0.0001 |
| Hematologic                    | 25 (26.6%)      | 229 (25.5%)     | 0.82 | 22 (25.6%)      | 214 (24.6%)     | 0.84 |
| Vasculitis                     | 42 (44.7%)      | 207 (23.1%)     | < 0.0001 | 36 (41.9%)      | 189 (21.7%)     | < 0.0001 |
| Immunologic                    | 82 (87.2%)      | 769 (85.7%)     | 0.69 | 76 (88.4%)      | 741 (85.2%)     | 0.42 |
| Serosal                        | 22 (23.4%)      | 112 (12.5%)     | 0.003 | 19 (22.1%)      | 94 (10.8%)      | 0.002 |
| Fever                          | 42 (44.7%)      | 231 (25.8%)     | < 0.0001 | 40 (46.5%)      | 200 (23.0%)     | < 0.0001 |
| Chronic renal insufficiency everf | 5 (5.3%)       | 64 (7.1%)       | 0.51 | 4 (4.7%)        | 60 (6.9%)       | 0.43 |
| Anti-phospholipid antibodiesg  |                 |                 |   |                 |                 |
| Ever from first clinic visit to last visit | 69 (75.8%)      | 546 (61.1%)     | 0.006 | 66 (76.7%)      | 527 (60.8%)     | 0.004 |
| Ever in the study period       | 66 (72.5%)      | 491 (55.0%)     | 0.001 | 61 (70.9%)      | 459 (53.0%)     | 0.001 |
| Corticosteroids                |                 |                 |   |                 |                 |
| At study start                 | 66 (76.7%)      | 559 (68.5%)     | 0.02 | 66 (70.2%)      | 557 (62.2%)     | 0.13 |
| Ever during follow-up          | 81 (94.2%)      | 676 (77.7%)     | 0.0003 | 88 (93.6%)      | 706 (78.7%)     | 0.0006 |
| Cumulative steroid dose (g)    |                 |                 |   |                 |                 |
| From first clinic visit to last visit | 42.3 ± 34.4    | 31.7 ± 34.7     | 0.006 | 43.5 ± 34.6     | 31.9 ± 35.1     | 0.005 |
| In the study period            | 30.3 ± 25.8     | 20.5 ± 23.1     | 0.0002 | 28.8 ± 25.1     | 19.7 ± 21.9     | 0.0005 |
| Antimalarialsj                 |                 |                 |   |                 |                 |
| At study start                 | 29 (33.7%)      | 356 (41.1%)     | 0.18 | 31 (33.0%)      | 349 (39.0%)     | 0.25 |
| Ever during follow-up          | 51 (59.3%)      | 622 (71.5%)     | 0.02 | 58 (61.7%)      | 639 (71.2%)     | 0.05 |

Nikpour et al. Arthritis Research & Therapy 2011, 13:R156
http://arthritis-research.com/content/13/5/R156
Page 5 of 14
Patients with CAD events were also more likely to have been older at lupus diagnosis (39.0 ± 14.1 versus 30.1 ± 13.5 years; \( P < 0.0001 \)) and to have anti-phospholipid antibodies (75.8% versus 61.1%; \( P = 0.006 \)), hypertension (82.6% versus 43.7%; \( P < 0.0001 \)), hypercholesterolemia (91.9% versus 68.6%; \( P < 0.0001 \)), and diabetes mellitus (15.1% versus 6.7%; \( P = 0.005 \)) during follow-up. In addition, they were more likely to be treated with corticosteroids (94.2% versus 77.7%; \( P = 0.0003 \)) at higher cumulative doses (42.3 ± 34.4 versus 31.7 ± 34.7 g; \( P = 0.006 \)).

### Table 2 Univariate comparison of patients with and without CAD used in TC and BP models (Continued)

|                         | Patients with CAD (n, %) | Patients without CAD (n, %) | \( P \) value |
|-------------------------|--------------------------|-----------------------------|--------------|
| **At study start**      |                          |                             |              |
| Hypertension\(^1\)     | 26 (31.0%)               | 123 (14.4%)                 | < 0.0001     |
| Hypercholesterolemia\(^1\) | 26 (31.0%)               | 350 (40.2%)                 | < 0.0001     |
| Diabetes mellitus\(^1\) | 5 (6.0%)                 | 29 (3.4%)                   | 0.22         |
| Smoker\(^3\)           | 20 (23.8%)               | 162 (19.0%)                 | 0.28         |
| Antihypertensives\(^4\) | 5 (6.0%)                 | 29 (3.4%)                   | 0.22         |
| Lipid-lowering medications\(^n\) | 1/10 (10.0%)           | 26/427 (6.1%)               | 0.48         |
| **Ever during follow-up** |                         |                             |              |
| Hypertension\(^1\)     | 46 (53.5%)               | 454 (52.2%)                 | 0.82         |
| Hypercholesterolemia\(^1\) | 71 (82.6%)               | 380 (43.7%)                 | < 0.0001     |
| Diabetes mellitus\(^1\) | 13 (15.1%)               | 597 (68.6%)                 | < 0.0001     |
| Smoker\(^3\)           | 27 (31.4%)               | 220 (25.4%)                 | 0.22         |
| Antihypertensives\(^4\) | 46 (53.5%)               | 454 (52.2%)                 | 0.82         |
| Lipid-lowering medications\(^n\) | 47/76 (90.8%)          | 355/487 (72.9%)             | 0.0008       |
| **TC level at study start** |                         |                             |              |
| Mean of first two TC levels\(^o\) | 5.85 ± 1.62              | 5.19 ± 1.56                 | < 0.0001     |
| Mean of all TC levels\(^o\) | 5.72 ± 1.23              | 4.95 ± 1.11                 | < 0.0001     |
| **AUC of all TC levels** |                         |                             |              |
| Mean of first two TC levels\(^o\) | 147/306 (48.1%)          | 166/642 (25.9%)             | 0.11         |
| Mean of all TC levels\(^o\) | 69/76 (90.8%)            | 355/487 (72.9%)             | 0.0008       |
| SBP at study start\(^o\) |                         |                             |              |
| Mean of first two SBPs\(^o\) | 134.90 ± 15.32           | 121.96 ± 14.81              | < 0.0001     |
| Mean of all SBPs\(^o\)  | 134.68 ± 15.35           | 121.88 ± 14.99              | < 0.0001     |
| AUC of all SBPs\(^o\)   | 13425 ± 1900             | 12303 ± 1735                | < 0.0001     |
| Mean of first two DBPs\(^o\) | 77.3 ± 12.3              | 80.8 ± 11.8                 | 0.009        |
| Mean of all DBPs\(^o\)  | 77.2 ± 10.5              | 82.0 ± 10.5                 | < 0.0001     |
| AM of all DBPs\(^o\)    | 76.2 ± 8.5               | 82.7 ± 6.7                  | < 0.0001     |
| AUC of all DBPs\(^o\)   | 179.476 ± 192,071        | 245.236 ± 194,324           | 0.002        |

AM, time-adjusted mean; AUC, area-under-the-curve; CAD, coronary artery disease; DBP, diastolic blood pressure; SBP, systolic blood pressure; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; TC, total plasma cholesterol (mmol/L). \(^a\)Menopause defined as a minimum of 12 months of amenorrhea irrespective of cause. \(^b\)Years. \(^c\)Scores range from 0 to 105, with higher scores indicating more-active disease. \(^d\)Disease manifestations defined based on SLEDAI-2K definitions. \(^e\)Chronic renal insufficiency defined based on SLICC/ACR DI definition (glomerular filtration rate < 50, proteinuria ≥3.5 g/24 h, or end-stage renal disease). \(^f\)Immunosuppressives include methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, and cyclophosphamide. \(^g\)Hypertension was defined as DBP ≥90 or SBP ≥140 mm Hg or treatment with antihypertensive medication. \(^h\)Hypercholesterolemia was defined as TC > 5.2 mmol/L or lipid-lowering therapy. \(^i\)Diabetes was defined as fasting plasma glucose > 7.0 mmol/L or diabetes therapy. \(^j\)Current smoking was defined as smoking of an average of one or more cigarettes per day over the past month. \(^k\)All classes of antihypertensives including diuretics, \(B\)-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin type II receptor blockers. \(^l\)HMG Co-A reductase inhibitors (statins). \(^m\)mmol/L. \(^n\)mmol/L multiplied by months.
antihypertensives (90.8% versus 72.9%; \( P = 0.0008 \)), and lipid-lowering medications (61.8% versus 26.5%; \( P < 0.0001 \)) during follow-up. Patients with CAD events were less likely to have been exposed to antimalarials during follow-up (59.3% versus 71.5%; \( P = 0.02 \)).

In the TC models, univariate comparison of patients with and without CAD outcomes revealed results that were similar to the BP models (Table 2). TC level at study start (5.85 ± 1.62 versus 5.19 ± 1.56 mmol/L; \( P = 0.0002 \)), average of first two TC levels (5.91 ± 1.53 versus 5.19 ± 1.49 mmol/L; \( P < 0.0001 \)), and mean (5.72 ± 1.23 versus 4.95 ± 1.11 mmol/L; \( P < 0.0001 \)), AM (5.72 ± 1.23 versus 4.94 ± 1.11; \( P < 0.0001 \)), and AUC (15, 806 ± 13, 063 versus 11, 1117 ± 11, 976 mmol/L; \( P = 0.0006 \)) of all serial TC levels were higher in patients who had CAD events than in those who remained CAD free.

In both the BP and TC datasets, patients with CAD events were more likely to have musculoskeletal, cutaneous, renal, and nervous system manifestations of lupus and were also more likely to have vasculitis, serositis, and fever during the course of their disease. However, no difference was found in the prevalence of chronic renal insufficiency, based on SLICC/ACR DI definition [10], among those with and without CAD (5.3% versus 7.1%; \( P = 0.51 \) in the BP dataset).

**Proportional hazards multiple regression models**

**TC models**

Table 3 shows the results of the proportional hazards models for CAD events by using various measures of TC. In the time-constant models (columns 1 and 2), neither first-available ("remote") TC nor the average of first two TC levels was significantly associated with a CAD event. However, in these models, male sex (HR = 2.01; \( P = 0.02 \) for first-available SBP model; HR = 2.04; \( P = 0.02 \) for average-of-first-two SBP model), age (HR = 1.05; \( P < 0.0001 \)) and SLEDAI-2K (HR = 1.03; \( P = 0.01 \)) at baseline, and steroid use ever (HR = 2.73 for first available and 2.74 for average of first two SBPs, \( P = 0.03 \)) were significantly associated with a CAD event. Antimalarial use ever was protective against CAD (HR = 0.59; \( P = 0.02 \)). Disease duration, elevated TC, and immunosuppressive use at baseline were not significantly associated with CAD.

In time-dependent models (Table 5, columns 3 to 5 inclusive), \( \text{mean} \) (HR = 1.025; \( P = 0.004 \)) and \( \text{AM} \) (HR = 1.024; \( P = 0.004 \)) SBP at each visit were significantly associated with a CAD event, with the same HR for each of these summary measures of SBP. In these models, other significant covariates included male sex (HR = 1.87; \( P = 0.04 \), for recent SBP model), age (HR = 1.06; \( P < 0.0001 \) for most recent SBP, HR = 1.04; \( P < 0.0001 \) for \( \text{mean} \) and \( \text{AM} \) SBP), SLEDAI-2K score (HR = 1.09; \( P < 0.0001 \) for all three models), and elevated cholesterol (HR = 1.72 for most recent, 1.68 for \( \text{mean} \), and 1.69 for \( \text{AM} \) SBP; \( P = 0.03 \) for all three models) at each visit. \( \text{AUC} \) SBP (Table 5, last column) was not significantly associated with CAD.

**DBP models**

Results of the proportional hazards models for CAD outcomes using various measures of diastolic blood pressure (DBP) were similar to the SBP models and are presented in Table 6.

In each of the multiple regression analyses presented in Tables 3 through 6, antiphospholipid antibodies, diabetes, and smoking were consistently statistically insignificant and therefore removed from the final models to maximize statistical power. Data on antihypertensive use and lipid-lowering therapy were incomplete for a proportion of visits. In subgroup analysis of these smaller datasets, neither antihypertensives nor lipid-lowering medications were significantly associated with CAD events (data not shown).

**Discussion**

Through the use of proportional hazards regression modeling in a large sample of more than 950 patients,
Table 3 Proportional hazards models for coronary outcomes using various measures of cholesterol

|                      | Time-constant models | Time-dependent models | Time-adjusted mean TC | AUC TC |
|----------------------|----------------------|-----------------------|-----------------------|--------|
|                      | First available ("remote") TC | Average of first two TCs | Most recent TC | Mean TC |                      |
| Cholesterol (TC)     | HR (95% CI) P         | HR (95% CI) P         | HR (95% CI) P       | HR (95% CI) P |                      |
|                      | 1.07 (0.93, 1.22) 0.36 | 1.08 (0.94, 1.24) 0.30 | 1.22 (1.05, 1.42) 0.01 | 1.22 (1.01, 1.47) 0.04 | 1.22 (1.02, 1.47) 0.03 | 1.00 (1.00, 1.00) 0.29 |
| Male sex             |                      |                       |                       |                    |
|                      | 2.02 (1.12, 3.62) 0.02 | 2.00 (1.11, 3.59) 0.02 | 1.84 (1.02, 3.32) 0.04 | 1.75 (0.97, 3.18) 0.06 | 1.74 (0.96, 3.15) 0.07 | 1.78 (0.98, 3.23) 0.06 |
| Age                  |                      |                       |                       |                    |
|                      | 1.06 (1.04, 1.08) < 0.0001 | 1.06 (1.04, 1.08) < 0.0001 | 1.06 (1.05, 1.08) < 0.0001 | 1.06 (1.05, 1.08) < 0.0001 | 1.06 (1.04, 1.08) < 0.0001 | 1.06 (1.04, 1.08) < 0.0001 |
| SLEDAI-2K            |                      |                       |                       |                    |
|                      | 1.03 (1.01, 1.06) 0.04 | 1.03 (1.00, 1.06) 0.06 | 1.09 (1.05, 1.13) < 0.0001 | 1.09 (1.05, 1.13) < 0.0001 | 1.09 (1.05, 1.13) < 0.0001 | 1.09 (1.05, 1.13) < 0.0001 |
| Hypertension         |                      |                       |                       |                    |
|                      | 1.12 (0.61, 2.04) 0.72 | 1.10 (0.60, 2.02) 0.76 | 1.50 (0.93, 2.42) 0.095 | 1.57 (0.97, 2.52) 0.06 | 1.57 (0.98, 2.52) 0.06 | 1.67 (1.05, 2.67) 0.03 |
| Corticosteroids      |                      |                       |                       |                    |
|                      | 4.17 (1.62, 10.73) 0.003 | 4.16 (1.62, 10.72) 0.003 | 1.85 (1.05, 3.23) 0.03 | 1.89 (1.08, 3.30) 0.03 | 1.89 (1.08, 3.30) 0.03 | 1.92 (1.10, 3.35) 0.02 |
| Antimalarials        |                      |                       |                       |                    |
|                      | 0.50 (0.31, 0.79) 0.003 | 0.50 (0.31, 0.80) 0.004 | 0.90 (0.57, 1.44) 0.066 | 0.88 (0.55, 1.41) 0.09 | 0.88 (0.55, 1.41) 0.06 | 0.80 (0.51, 1.27) 0.35 |
| Immunosuppressives   |                      |                       |                       |                    |
|                      | 0.79 (0.49, 1.26) 0.32 | 0.78 (0.49, 1.25) 0.30 | 1.32 (0.62, 2.14) 0.25 | 1.29 (0.79, 2.08) 0.31 | 1.29 (0.79, 2.09) 0.31 | 1.34 (0.83, 2.17) 0.23 |

95% CI, 95% confidence interval; AUC, area under the curve; BP, blood pressure (mm Hg); DBP, diastolic blood pressure (mm Hg); HR, hazard ratio; NS: not significant; P, P value; SBP, systolic blood pressure (mm Hg); TC, total plasma cholesterol (mmol/L).

Years; age at the time of first available TC (or SBP or DBP) in time-constant models and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models. SLE Disease Activity Index 2000; scores range from 0 to 105, with higher scores indicating more-active disease; measured at the time of first available TC (or SBP or DBP) in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models.

Hypertension defined as diastolic BP ≥90 or systolic BP ≥140 mm Hg; defined as present ever during the study in time-constant models, and coincident with each TC measurement in the time-dependent covariate models.

Corticosteroids defined as used ever during the study in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models.

Elevated total plasma cholesterol (hypercholesterolemia) defined as total plasma cholesterol > 5.2 mmol/L; measured at the time of first available SBP or DBP in time-constant models, and coincident with each TC measurement in the time-dependent covariate models.

Antimalarials include chloroquine and hydroxychloroquine; defined as used ever during the study in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models.

Immunosuppressives include methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, and cyclophosphamide; defined as used ever during the study in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models.
in whom collectively more than 18,000 serial measurements of TC and BP were taken over a mean duration of 6.3 years, we were able to demonstrate and quantify the association between several important risk factors and CAD events in SLE.

Foremost, this study highlights the important role of traditional risk factors such as elevated TC and BP in SLE-related CAD and demonstrates a continuum of risk associated with these variables across the range of possible values they may assume. Previous studies have shown that traditional risk factors, such as hypercholesterolemia and hypertension, account for only a small proportion of the increased risk of CAD in SLE. However, in these studies, TC and BP were measured at baseline, in keeping with the premise of the Framingham model. Here we have shown that this remote measure of exposure to TC, SBP, or DBP is not predictive of CAD outcome among patients with SLE. Furthermore, recent measurements of TC and BP, which are also taken at a single point in time, are not able to quantify CAD risk to the same degree as "summary measures," which capture cumulative exposure to these risk factors over the course of disease. We have previously shown that, unlike the general population, wherein TC and BP "track" over time, in patients with SLE, these risk factors take a dynamic course, varying because of changes in disease activity and treatment [5].

In this study, cumulative exposure to TC, SBP, and DBP was measured by using three summary measures, arithmetic mean, time-adjusted mean (AM), and area-under-the-curve (AUC). Time-dependent proportional hazards regression models were then applied to these summary measures. In this way, a sense of cumulative exposure was captured in two ways: first, in the form of a summary measure, and second, by determining the hazard related to this summary measure for an interval just before each and every sequential visit. In these time-dependent models, a sense of cumulative exposure to other covariates, including disease activity score, corticosteroids, and antimalarials, was also captured through the use of serial measurements of these variables, updated from one visit to the next.

For each of TC, SBP, and DBP, mean and AM summary measures were significantly predictive of a CAD event. In addition, the HR and accompanying P value of mean summary measures was the same as for AM summary measures in the case of each of TC, SBP, and DBP. This is likely related to the fact that overall, in this context, in which measurements were taken frequently, mean and AM values were very similar for each patient. However, when applied to a setting in which measurements are more irregular and infrequent, the AM, which is weighted for the interval between measurements, may be expected more accurately to reflect cumulative risk.

### Table 4 Proportional hazards models for coronary outcomes using various measures of cholesterol, including only significant covariates in the models

|                         | Time-dependent covariate models |                     |                     | Time-dependent covariate models |                     |                     |
|-------------------------|-------------------------------|---------------------|---------------------|-------------------------------|---------------------|---------------------|
|                         | Most recent TC                | Mean TC             | Time-adjusted mean TC |
|                         | HR (95% CI)                  | P                   | HR (95% CI)        | P               | HR (95% CI)        | P               |
| Cholesterol (TC)        | 1.86 (1.30, 2.68)             | 0.001               | 2.07 (1.28, 3.36)  | 0.003            | 2.07 (1.28, 3.34)  | 0.003            |
| Male sex                | 1.90 (1.06, 3.41)             | 0.03                | 1.83 (1.01, 3.29)  | < 0.0001         | 1.82 (1.01, 3.29)  | 0.047            |
| Age<sup>a</sup>         | 1.12 (1.07, 1.17)             | < 0.0001            | 1.13 (1.06, 1.20)  | < 0.0001         | 1.13 (1.06, 1.20)  | < 0.0001         |
| SLEDAI-2K<sup>¶</sup>   | 1.09 (1.05, 1.13)             | < 0.0001            | 1.10 (1.06, 1.12)  | < 0.0001         | 1.10 (1.06, 1.12)  | < 0.0001         |
| Corticosteroids<sup>b</sup> | 2.04 (1.20, 3.45)             | 0.01                | 2.01 (1.19, 3.41)  | 0.01             | 2.01 (1.19, 3.41)  | 0.01             |

|                          |                              |                     |                     |                          |                     |                     |
| 95% CI, 95% confidence interval; AUC, area under the curve; BP, blood pressure (mm Hg); DBP, diastolic blood pressure (mm Hg); HR, hazard ratio; NS, not significant; P, value; SBP, systolic blood pressure (mm Hg); TC, total plasma cholesterol (mmol/L). |

<sup>a</sup>Years: age at the time of first available TC (or SBP or DBP) in time-constant models and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models. 
<sup>b</sup>Hypertension defined as diastolic BP > 90 or systolic BP ≥ 140 mm Hg; defined as present ever during the study in time-constant models, and coincident with each TC measurement in the time-dependent covariate models. 
<sup>¶</sup>Corticosteroids defined as used ever during the study in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models. 
<sup>¶</sup>SLE Disease Activity Index 2000; scores range from 0 to 105, with higher scores indicating more-active disease; measured at the time of first available TC (or SBP or DBP) in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models. 
<sup>¶</sup>Elevated total plasma cholesterol (hypercholesterolemia) defined as total plasma cholesterol > 5.2 mmol/L; measured at the time of first available SBP or DBP in time-constant models, and coincident with each SBP or DBP measurement in the time-dependent covariate models. 
<sup>¶¶</sup>Antimalarials include chloroquine and hydroxychloroquine; defined as used ever during the study in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models. 
<sup>¶¶</sup>Immunosuppressives include methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, and cyclophosphamide; defined as used ever during the study in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models.
Table 5 Proportional hazards models for coronary events using various measures of systolic blood pressure

| Time-constant models | Time-dependent models | AUC SBP |
|----------------------|-----------------------|---------|
| First available ("remote") SBP | Mean SBP | First two SBP | Most recent SBP | Mean SBP | Time-adjusted mean SBP |
| **Systolic blood pressure (SBP)** | **HR (95% CI)** | **P** | **HR (95% CI)** | **P** | **HR (95% CI)** | **P** | **HR (95% CI)** | **P** | **HR (95% CI)** | **P** |
| 1.00 (0.99, 1.02) | 0.45 | 1.31 (0.68, 2.53) | 0.42 | 1.01 (1.00, 1.02) | 0.052 | 1.025 (1.01, 1.04) | 0.004 | 1.024 (1.01, 1.04) | 0.004 | 1.00 (1.00, 1.00) | 0.19 |
| **Male sex** | 2.01 (1.13, 3.59) | 0.02 | 2.04 (1.14, 3.65) | 0.02 | 1.87 (1.03, 3.39) | 0.04 | 1.75 (0.96, 3.21) | 0.07 | 1.74 (0.95, 3.18) | 0.07 | 1.83 (1.00, 3.33) | 0.049 |
| **Age** | 1.05 (1.03, 1.07) | < 0.0001 | 1.05 (1.03, 1.07) | < 0.0001 | 1.06 (1.03, 1.07) | < 0.0001 | 1.04 (1.02, 1.07) | < 0.0001 | 1.04 (1.02, 1.07) | < 0.0001 | 1.06 (1.04, 1.08) | < 0.0001 |
| **SLEDAI-2K** | 1.03 (1.01, 1.06) | 0.01 | 1.03 (1.01, 1.06) | 0.01 | 1.09 (1.05, 1.13) | < 0.0001 | 1.09 (1.05, 1.13) | < 0.0001 | 1.09 (1.05, 1.13) | < 0.0001 | 1.09 (1.05, 1.13) | < 0.0001 |
| **Elevated cholesterol** | 1.41 (0.67, 2.98) | 0.37 | 1.39 (0.66, 2.95) | 0.39 | 1.72 (1.06, 2.78) | 0.03 | 1.68 (1.04, 2.71) | 0.03 | 1.69 (1.04, 2.73) | 0.03 | 1.82 (1.13, 2.92) | 0.01 |
| **Corticosteroids** | 2.73 (1.13, 6.61) | 0.03 | 2.74 (1.13, 6.62) | 0.03 | 1.74 (0.99, 3.08) | 0.06 | 1.72 (0.98, 3.03) | 0.06 | 1.72 (0.97, 3.03) | 0.06 | 1.77 (1.00, 3.12) | 0.049 |
| **Antimalarials** | 0.59 (0.37, 0.93) | 0.02 | 0.59 (0.37, 0.95) | 0.03 | 0.95 (0.60, 1.52) | 0.84 | 0.97 (0.61, 1.56) | 0.91 | 0.97 (0.61, 1.55) | 0.93 | 0.75 (0.58, 1.48) | 0.75 |
| **Immunosuppressives** | 0.91 (0.58, 1.43) | 0.68 | 0.89 (0.56, 1.41) | 0.63 | 1.51 (0.93, 2.45) | 0.10 | 1.48 (0.91, 2.40) | 0.11 | 1.48 (0.91, 2.40) | 0.11 | 1.46 (0.90, 2.36) | 0.13 |

95% CI: 95% confidence interval; AUC: area under the curve; BP: blood pressure (mmHg); DBP: diastolic blood pressure (mmHg); HR: hazard ratio; NS: not significant; p: p value; SBP: systolic blood pressure (mmHg); TC: total plasma cholesterol (mmol/L).

1Years; age at the time of first available TC (or SBP or DBP) in time-constant models and coincident with each TC (or SBP or DBP) in time-dependent models, and coincident with each TC (or SBP or DBP) in time-constant models and coincident with each TC (or SBP or DBP) in time-dependent models. 2Hypertension defined as Diastolic BP ≥ 90 or Systolic BP ≥ 140 mmHg; defined as present ever during the study in time-constant models, and coincident with each TC (or SBP or DBP) in time-dependent models. 3SLE Disease Activity Index 2000; scores range from 0 to 105, with higher scores indicating more active disease; measured at the time of first available TC (or SBP or DBP) in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models. 4Antimalarials include chloroquine and hydroxychloroquine; defined as used ever during the study in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models. 5Immunosuppressives include methotrexate, azathioprine, mycophenolate mofetil, cyclosporine and cyclophosphamide; defined as used ever during the study in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models.
|                      | Time-constant models |                      | Time-dependent models |                      |                      |                      |                      |
|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
|                      | First available ('remote') DBP | Average of first two DBP |                      | Most recent DBP | Mean DBP |                      |                      | AUC DBP |
|                      | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p |
| Diastolic blood pressure (DBP) | 1.00 (0.98, 1.02) | 0.87 | 1.01 (0.99, 1.03) | 0.46 | 1.02 (1.003, 1.05) | 0.02 | 1.04 (1.01, 1.07) | 0.02 | 1.04 (1.01, 1.07) | 0.02 | 1.00 (1.00, 1.00) | 0.94 |
| Male sex | 2.01 (1.13, 3.60) | 0.02 | 2.00 (1.12, 3.58) | 0.02 | 1.85 (1.02, 3.36) | 0.04 | 1.72 (0.94, 3.15) | 0.08 | 1.70 (0.93, 3.11) | 0.09 | 1.88 (1.03, 3.43) | 0.39 |
| Age$^\psi$ | 1.05 (1.04, 1.07) | < 0.0001 | 1.05 (1.04, 1.07) | < 0.0001 | 1.06 (1.04, 1.08) | < 0.0001 | 1.06 (1.04, 1.08) | < 0.0001 | 1.06 (1.04, 1.07) | < 0.0001 | 1.06 (1.04, 1.08) | < 0.0001 |
| SLEDAI-2K$^\psi$ | 1.03 (1.01, 1.06) | 0.01 | 1.03 (1.01, 1.06) | 0.01 | 1.09 (1.05, 1.13) | < 0.0001 | 1.09 (1.05, 1.13) | < 0.0001 | 1.09 (1.05, 1.13) | < 0.0001 | 1.09 (1.05, 1.13) | < 0.0001 |
| Elevated cholesterol$^\psi$ | 1.42 (0.67, 3.00) | 0.36 | 1.40 (0.66, 2.96) | 0.38 | 1.70 (1.05, 2.74) | 0.03 | 1.70 (1.06, 2.75) | 0.03 | 1.69 (1.04, 2.73) | 0.03 | 1.86 (1.16, 2.99) | 0.01 |
| Corticosteroids$^b$ | 2.81 (1.16, 6.80) | 0.02 | 2.74 (1.13, 6.63) | 0.03 | 1.75 (0.99, 3.10) | 0.054 | 1.76 (1.00, 3.11) | 0.051 | 1.72 (0.97, 3.03) | 0.06 | 1.81 (1.02, 3.19) | 0.04 |
| Antimalarials$^\zeta$ | 0.57 (0.36, 0.90) | 0.02 | 0.59 (0.37, 0.94) | 0.03 | 0.95 (0.60, 1.51) | 0.082 | 0.96 (0.60, 1.53) | 0.085 | 0.96 (0.60, 1.53) | 0.085 | 0.92 (0.58, 1.47) | 0.73 |
| Immunosuppressives$^¥$ | 0.91 (0.58, 1.43) | 0.68 | 0.89 (0.56, 1.41) | 0.61 | 1.45 (0.85, 2.34) | 0.13 | 1.37 (0.85, 2.23) | 0.20 | 1.38 (0.85, 2.23) | 0.20 | 1.43 (0.88, 2.32) | 0.14 |

95% CI: 95% confidence interval; AUC: area under the curve; BP: blood pressure (mmHg); DBP: diastolic blood pressure (mmHg); HR: hazard ratio; NS: not significant; p: p value; SBP: systolic blood pressure (mmHg); TC: total plasma cholesterol (mmol/L).

$^\psi$Years: age at the time of first available TC (or SBP or DBP) in time-constant models and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models. $^\psi$SLE Disease Activity Index 2000; scores range from 0 to 105, with higher scores indicating more active disease; measured at the time of first available TC (or SBP or DBP) in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models. $^\psi$Hypertension defined as Diastolic BP $\geq$ 90 or Systolic BP $\geq$ 140 mmHg; defined as present ever during the study in time-constant models, and coincident with each TC measurement in the time-dependent covariate models. $^\psi$Total plasma cholesterol > 5.2 mmol/L; measured at the time of first available SBP or DBP in time-constant models, and coincident with each SBP or DBP measurement in the time-dependent covariate models. $^\psi$Antimalarials include chloroquine and hydroxychloroquine; defined as used ever during the study in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models. $^\psi$Immunosuppressives include methotrexate, azathioprine, mycophenolate mofetil, cyclosporine and cyclophosphamide; defined as used ever during the study in time-constant models, and coincident with each TC (or SBP or DBP) measurement in the time-dependent covariate models.
exposure and hence the overall risk of CAD. In the case of TC, a hazard ratio of 2.07 ($P = 0.003$) means that for every 1 mmol/L increase in mean (or AM) plasma TC level, the hazard of a CAD outcome increases 2.07-fold. In the case of SBP, a hazard ratio of 1.025 means that for every 1-mm Hg increase in mean SBP, the hazard of CAD outcome increases 1.025-fold.

Likewise, in the case of DBP, a hazard ratio of 1.04 means that for every 1-mm Hg increase in mean (or AM) DBP, the hazard of CAD outcome increases 1.04-fold. SBP and DBP are highly correlated, and, based on our analyses, either one or the other may be used to quantify CAD risk in patients with SLE.

AUC is very closely tied to length of follow-up, and for any given variable may only become larger over time. As such, it does not provide a sense of rise and fall in the variable of interest. Furthermore, it is not measured in the original units of the variable from which it is derived. These reasons may underlie the lack of association between AUC measures and CAD outcomes among SLE patients in our study.

In this proof-of-concept study, our chosen lipid marker of CAD risk was TC. In general, low-density lipoprotein cholesterol (LDL-C) is deemed the primary target of lipid-lowering therapy [11]. In the Toronto lupus cohort, measurement of nonfasting TC has been routine practice at every visit since 1975. However, measurement of lipid and lipoprotein subfractions is a more-recent addition to the data-collection protocol and performed only once yearly because of the need for a fasting sample. To derive summary measures and test their ability to quantify CAD risk, we required a very large dataset inclusive of a relatively large number of CAD outcomes. The TC and BP datasets fulfilled these methodologic requirements. In future, summary measures derived in this study may be applied to other risk factors, such as LDL-C.

How many measurements are enough to provide a valid summary measure, and how often should these measurements be taken in patients with SLE? In this study, the average of first two TC (or SBP or DBP) measurements was not significantly predictive of CAD outcome. Therefore, ideally three or more serial measurements should be sought. Although in this study, the mean gap between measurements used to calculate summary measures was 4.3 months, patients in whom the gap between one or more serial measurements exceeded 18 months were not included in the analyses. Further studies are required to determine the optimal number and frequency of measurements of TC and BP in evaluating CAD risk in SLE.

This study has provided several important insights into the role of demographic-, disease-, and treatment-related variables in SLE-related CAD. The most noteworthy are the increased risk of CAD with increasing disease activity and corticosteroid use, and the protective effect of antimalarials.

We found that for every unit increase in recent SLEDAI-2K disease activity score, the risk of CAD event by the time of the subsequent visit increased almost 10%. An increase in SLEDAI-2K score of 4 or more is generally deemed clinically significant [12]. This means that a minimum clinically significant increase in recent disease activity score is associated with approximately 46% increase in risk of CAD in the interval between sequential visits. Ibanez et al. [13] previously showed that for every unit increase in the time-adjusted mean SLEDAI-2K score (AMS), the hazard of a CAD outcome increases 1.08-fold. Collectively, these associations highlight the underpinning role of inflammation in SLE-related CAD.

Our patients with CAD events had greater disease activity at baseline and during follow-up, manifest in a multitude of organ systems, including musculoskeletal, cutaneous, renal, neural, vascular, and serosal. As the overall prevalence of chronic renal impairment was low and did not differ among groups with and without CAD, the association between disease activity and events seen in this study cannot be attributed to nephritis or renal impairment alone.

In studies of coronary risk factors in SLE, it is often difficult to tease apart the effect of corticosteroids from disease activity and traditional cardiac risk factors. In previous studies, longer duration of steroid use has been shown to be an independent risk factor for CAD in SLE [1,14]. With a retrospective chart review method, Karp et al. [15] showed that a 10-mg increase in the average daily prednisone-equivalent dose in the preceding year is independently associated with a 16% increase in the estimated 2-year CAD risk. Here, we quantified the CAD risk in patients with SLE by using prospectively collected data. Patients with CAD events received a significantly greater cumulative dose of corticosteroids during follow-up than did those who remained CAD free. In the regression models for first-available and average-of-first-two TC levels, exposure to corticosteroids at any time during the course of disease, irrespective of dose and duration of use, was associated with a dramatic 4.17-fold increased risk of a CAD event, independent of other risk factors. This HR was reduced to 1.85, but remained substantial and statistically significant, in the time-dependent models wherein recent exposure to corticosteroids was related to a CAD event.

In time-constant models for TC and BP, antimalarial use during the course of SLE was associated with a remarkable 50% to 59% reduction in hazard of a CAD event. The lack of a significant association between recent antimalarial use and CAD in the time-dependent
models may point to a beneficial effect with long-term rather than short-term use. In previous studies, use of antimalarials has been associated with a reduction in TC level [5,14,16,17]. However, ours is one of only a few studies in which the use of antimalarials has been linked with a reduction in the risk of actual CAD events [18,19]. Furthermore, the halving of coronary risk makes a strong case for the use of antimalarials in patients with SLE, not only to control disease activity but also for cardioprotection.

As in previous studies, we have shown that male sex and older age are associated with increased hazard of a CAD event. In previous studies, anti-phospholipid antibodies, diabetes, and smoking were shown to be independent risk factors for CAD events in SLE [20]. However, in this study, in multiple regression analysis, such an association was not found, possibly because of the limited number of patients who smoke or have diabetes or anti-phospholipid antibodies. This study is not an exhaustive evaluation of traditional risk factors, and the role of other variables, such as family history of ischemic heart disease, body mass index (BMI), and waist/hip ratio, merit further investigation in future studies.

In summary, we showed that elevated TC and BP are both potentially treatable risk factors for CAD in SLE. Our study highlighted the importance of frequent measurements of BP and TC in management of patients with SLE. Although clinicians might consider the need for change in treatment based on single TC and BP measurements, their decision actually to do so should be made on the basis of the mean of several measurements.

Conclusions
Overall, this study has both conceptual and practical significance. From a conceptual point of view, our findings illustrate that in a systemic inflammatory disease, for a dynamic risk factor such as TC or BP, summary measures such as mean and AM better reflect cumulative exposure and hence better quantify CAD risk. This is an important consideration in future studies of dynamic risk factors for CAD in a chronic relapsing-remitting disease such as SLE and may be used to derive risk-prediction models specifically for SLE. From a practical point of view, this study has shown that assessment of coronary risk related to TC and BP in patients with SLE relies on serial measurement of these risk factors throughout the relapsing-remitting course of SLE. Additionally, this study has shown that disease activity and corticosteroid use are CAD risk factors in SLE, indicating that disease activity should be recognized and optimally controlled by using the minimal effective dose of corticosteroids. The demonstration of a cardioprotective association of antimalarials highlights the staple role of this class of drugs in the management of patients with SLE. Finally, this study has quantified the risk associated with exposure to TC, SBP, and DBP over time, emphasizing the importance of these potentially treatable traditional risk factors in patients with SLE. Future efforts must be directed toward determining TC and BP cut-points for CAD risk stratification specifically among patients with SLE and the role of treatment of risk factors in reducing the incidence of CAD events.

Abbreviations
ACR: American College of Rheumatology; AM: time-adjusted mean; AMS: adjusted mean SLE disease activity index 2000; AUCl: area under the curve; BP: blood pressure; CAD: coronary artery disease; CI: confidence interval; DBP: diastolic blood pressure; ECG: electrocardiographic; HR: hazard ratio; LDL-C: low-density lipoprotein cholesterol; Max: maximum; Min: minimum; mm Hg: millimeters of mercury: mmol/L: millimoles per liter; MI: myocardial infarction; SBP: systolic blood pressure; SD: standard deviation; SLE: systemic lupus erythematosus; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000; SLICC/ACR DI: Systemic Lupus Erythematosus International Collaborating Clinics/American College of Rheumatology Damage Index; TC: total cholesterol.

Acknowledgements
This study was supported by the Centre for Prognosis Studies in The Rheumatic Diseases, The Smythe Foundation, Lupus Flare Foundation, Ontario Lupus Association, and The Lupus Society of Alberta. Dr. Nikpour was supported by the Arthritis Centre of Excellence and the Geoff Carr Lupus Fellowship.

Authors’ contributions
MN participated in the study design, collection and analysis of data, interpretation of results, and preparation of the manuscript. DDG and MBU participated in the study design, collection of data, interpretation of results, and preparation of the manuscript. PJH participated in the study design, interpretation of results, and preparation of the manuscript. All authors read and approved the manuscript for publication.

Competing interests
The authors declare that they have no competing interests.

Received: 24 May 2011 Revised: 17 August 2011 Accepted: 29 September 2011 Published: 29 September 2011

References
1. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, D’Agostino RB, Kuller LH: Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997, 145:408-415.
2. Eddleal JM, Abrahamovicz M, Grodzicky T, Li Y, Panantis C, du Berger R, Cote R, Grover SA, Fortin PR, Clarke AE, Senecal JI: Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44:2331-2337.
3. Vasan RS, D’Agostino RB Sr: Age and time need not and should not be eliminated from the coronary risk prediction models. Circulation 2005, 111:542-545.

4. Bruce IN, Urowitz MB, Gladman DD, Hallett DC: Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999, 26:2137-2143.

5. Nikpour M, Gladman DD, Ibanez D, Harvey PJ, Urowitz MB: Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study. Arthritis Res Ther 2010, 12:R25.

6. Lee P, Urowitz MB, Bookman AA, Koehler BE, Smythe HA, Gordon DA, Ogoylo MA: Systemic lupus erythematosus: a review of 110 cases with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis. Q J Med 1977, 46:1-32.

7. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.

8. Craig SR, Amin RV, Russell DW, Paradise NF: Blood cholesterol screening influence of fasting state on cholesterol results and management decisions. J Gen Intern Med 2000, 15:395-399.

9. Gladman DD, Ibanez D, Urowitz MB: Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002, 29:288-291.

10. Gladman D, Gaderie E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snash M, Sturfeld G, Symmons D, Zoma A: The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996, 39:363-369.

11. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.

12. Gladman DD, Urowitz MB, Kagal A, Hallett D: Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol 2000, 27:377-379.

13. Ibanez D, Gladman DD, Urowitz MB: Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 2005, 32:824-827.

14. Petri M, Lakatta E, Magder L, Goldman D: Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Arq J Med 1994, 96:254-259.

15. Karp I, Abrahamowicz M, Fortin PR, Pilote L, Neville C, Pineau CA, Esdaile JM: Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis Rheum 2000, 43:169-175.

16. Sacher JC, Borba EF, Bortol E, Vinagre CG, Silva VM, Maranhao RC: Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 2007, 16:273-278.

17. Wallace DJ, Metzger AI, Stecher VJ, Turnbull BA, Korn PA: Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990, 89:322-326.

18. Goldberg RJ, Urowitz MB, Ibanez D, Nikpour M, Gladman DD: Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. J Rheumatol 2009, 36:2454-2461.

19. Ruiz-Trasviña G, Ramos-Casals M, Brito-Zeron P, Khamash MA: Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010, 69:20-28.

20. Gladman DD, Urowitz MB: Morbidity in systemic lupus erythematosus. J Rheumatol Suppl 1987, 14(Suppl 13):223-226.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Cite this article as: Nikpour et al: Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. Arthritis Research & Therapy 2011 13:R156.
Author/s: 
Nikpour, M; Urowitz, MB; Ibanez, D; Harvey, PJ; Gladman, DD

Title: 
Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study

Date: 
2011-01-01

Citation: 
Nikpour, M; Urowitz, MB; Ibanez, D; Harvey, PJ; Gladman, DD, Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study, ARTHRITIS RESEARCH & THERAPY, 2011, 13 (5)

Persistent Link: 
http://hdl.handle.net/11343/221580

File Description: 
Published version